Cardiothoracic & vascular anesthesia

High Postreperfusion Pulmonary Artery Pressure Is Associated With Increased 30-Day Mortality in Liver Transplantation

J Cardiothorac Vasc AnesthPublished Retrospective cohort study

Main finding · Association of elevated postreperfusion mPAP with 30-day mortalityResult — go to the resultOdds ratio 6.056 95% CI 2.349–15.611

Authors' conclusion

This retrospective study found a 7.3% rate of high PAP following reperfusion in LT, and high postreperfusion PAP was associated with 30-day mortality.

Study context

Population
Consecutive adults undergoing liver transplantation at a university tertiary centre, 2013–2023
Participants
1,243 adults
Exposure
Elevated vs non-elevated postreperfusion mean pulmonary artery pressure (mPAP)
  • Elevated mPAPn = 91
Outcome
Association of elevated postreperfusion mPAP with 30-day mortality
Follow-up
30 days
Methodological detailssingle-centre, consecutive patients
  • Single-centre
  • Consecutive patients

Main finding

As reported in the abstract

Odds ratio

6.056

95% CI 2.349–15.611

P < 0.001

Elevated mPAP vs Non-elevated mPAP
OR 6.056 (95% CI 2.349–15.611); P < 0.001

Observational data: associations, not effects.

Further findings

Incidence of elevated postreperfusion mPAP · first hour after reperfusion — Elevated mPAP
7.3%

Risk factors for elevated postreperfusion mPAP (multivariable logistic regression)

Preoperative elevated PAP on echocardiogram, preoperative serum creatinine and intraoperative epinephrine use were significant risk factors

30-day mortality, whole cohort

Died within 30 days after liver transplantation (LT)
32 (1.9%)

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

High Postreperfusion Pulmonary Artery Pressure Is Associated With Increased 30-Day Mortality in Liver Transplantation. J Cardiothorac Vasc Anesth. Published 4 September 2024. doi:10.1053/j.jvca.2024.08.041

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.